Stipple Bio was founded by cancer biology pioneers and is led by experts in cancer drug development
Stipple Bio was founded in 2022 by cancer biology pioneers Dr. Aaron Ring, Associate Professor at Fred Hutch and Dr. Aashish Manglik, Associate Professor at UCSF, who believed that targeting tumor-specific cell surface epitopes could improve therapeutic index and unlock targets previously intractable with conventional drug discovery methods.
Investors a16z Bio+Health, Yosemite and OMX provided Stipple Bio’s initial Seed financing.
Leadership Team
Our leadership has deep experience and success discovering, developing, and commercializing oncology products.
Stipple Bio is based in Cambridge, MA.
Jeff Landau, MBA 
Chief Executive Officer
Michelle Zhang, PhD
Chief Scientific Officer
Andrew "Andi" Lake, PhD
Vice President of Translational Biology
Board of Directors
Vineeta Agarwala, MD, PhD
General Partner, Andreessen Horowitz (a16z)
Leadership Team
Our investors are committed to our mission of revolutionizing targeted oncology with epitope level precision to develop life-changing medicines for people with cancer.
